ArticleOncotarget2016

Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma.

Matthew J Martin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.